Abstract: New synthetic routes to kahalalide compounds are provided. These are based on convergent approaches using orthogonal protecting schemes, where a better control of the intermediates is taken. Kahalalide F or a mimic of kahalalide F is synthesised by coupling a cyclic part with a side chain fragment, e.g.

Abstract: The present application relates to new peptide polymers comprising monomeric units derived from the residues of glutamic acid, aspartic acid and lysine, or their protected derivatives, and which are functionalized through the introduction of side chains containing thiol groups or protected thiol groups. The new peptide polymers can be crosslinked in aqueous medium, and the resulting polymer matrices have the capacity to entrap drugs and, subsequently, release them in a controlled way when introduced into a physiological medium. This enables new pharmaceutical compositions to be developed for the controlled release of drugs, especially peptide- and protein-based ones.

Abstract: New analogues of kahalalide F are provided.

Abstract: Serratamolide, also named cyclo[(3R)-3-hydroxydecanoyl-L-seryl-(3R)-3-hydroxydecanoyl-L-seryl], is a cyclic depsipeptide isolated from cultures of bacteria of the species Serratia marcescens. Serratamolide decreases the viability of, and induces apoptosis in several cancer cells (leukemias, myelomas, carcinomas, etc.), virtually with no effect on non-cancer cells. This makes serratamolide, and its pharmaceutically acceptable addition salts and/or solvates, useful as anticancer chemotherapeutic agent, particularly against leukemia, lymphoma, myeloma, carcinoma, melanoma and sarcoma.

Abstract: Trunkamide A and other cyloheptatides can be made by solid phase synthesis of a linear precursor.